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Drug-targeting to the kidney: Renal delivery and degradation of a
naproxen-lysozyme conjugate in vivo. A renal-specific controlled release
of an active drug may enable a reduction of the required dose and may
provide a reduction of extra-renal toxicity. To achieve renal specific
targeting of the NSAID naproxen, the low-molecular-weight protein
(LMWP) lysozyme was employed as carrier since it is mainly taken up and
catabolized in the proximal tubules of the kidney. A conjugate was
synthesized with an average coupling degree of 2 mol naproxen per 1 mol
lysozyme in which the drug was directly coupled to the protein via a
peptide bond. First, we investigated whether naproxen conjugation affects
the renal disposition of lysozyme. As native lysozyme, the conjugate was
predominantly and rapidly (within 20 mm) taken up by the kidney. The
subsequent decrease in renal content reflecting the renal degradation of
the conjugated lysozyme molecules appeared also to be similar to that of
native lysozyme with a half life of four hours. Second, the effect of
lysozyme conjugation on the body distribution of naproxen was studied.
An important observation with regard to the aimed reduction in extra-
renal side effects was that no detectable amounts of free naproxen were
present in the plasma after administration of conjugate. Conjugation of
naproxen to lysozyme resulted in a pronounced (70-fold) increase of
naproxen accumulation in the kidney. In agreement with the protein
disposition study, the conjugate was rapidly taken up by the kidney and
subsequently degraded. In conclusion, renal selective targeting of the
NSAID naproxen can be obtained by conjugation with the LMWP
lysozyme. This concept of drug delivery to the kidney has the potential to
improve drug efficacy and safety.
Drug targeting to the kidney may be of interest for drugs, such
as non-steroidal anti-inflammatory drugs (NSAIDs) that are
beneficial in the kidney [1] but are toxic elsewhere in the body [2].
To achieve renal specific targeting, low-molecular-weight proteins
(LMWP) may serve as carriers. They arc rather freely filtered and
after reabsorption by the proximal tubular cells, catabolized in the
lysosomes [3—51. Our concept is based on the idea that drugs
attached to such a protein will also he carried via this intrarenal
route into the proteolytic active lysosomes and released from their
protein carrier during catabolism.
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Franssen et al [61 tested the feasibility of using the LMWP
lysozyme as carrier for the renal delivery of the NSAID naproxen.
The study showed that after an intravenous injection of the
conjugate in the rat, the plasma disappearance of naproxen-
lysozyme conjugate was similar to that of native lysozyme and
clearly different from that of unbound naproxen. This indicates
that the conjugate is distributed in the body like native lysozyme,
and thus is predominantly taken up by the kidney. Although the
data indicated renal selective targeting, direct evidence for this
was not obtained.
In the present study, we measured the renal specificity of a
naproxen-lysozyme conjugate directly. Protein (lysozyme) kinetics
and drug (naproxen) kinetics were evaluated with special empha-
sis on the uptake and degradation in the actual target organ, the
kidney. The first observation of renal activity of the naproxen-
lysozyme conjugate is also presented.
METHODS
Chemicals
Lysozyme, the sodium salt of naproxen (Nap), ketoprofen and
N-hydroxysuccinimide (NHS) were purchased from Sigma (Axel,
The Netherlands). Dicyclohexylcarbodiimide was obtained from
Aldrich Chemica Co. (Gillingham, Dorset, UK). Water was of
millipore quality. All other chemicals were of analytical grade.
The prostaglandin E2 enzymeimmunoassay system was obtained
from Amersham Life Science (Amersham, s'-Hertogenbosch, The
Netherlands).
Synthesis of naproxen-N-hydroxysuccinimide ester
To obtain a sufficient conjugation with lysozyme, naproxen was
preactivated with N-hydroxysuccinimide. The synthesis of the
N-hydroxysuccinimide ester of naproxen (Nap-NHS) was per-
formed according to Anderson, Zimmerman and Callahan [71. Tn
70 ml tetrahydrofuran, 2 g (8.6 mmol) Nap and 1.5 g (13 mmol)
NHS were dissolved. After cooling down to —15°C, 2,5 g (12.5
mmol) dicyclohcxylcarbodiimide in tetrahydrofuran was added.
The mixture was stirred for one hour at —15°C followed by 20
hours at room temperature. The precipitate dicyclohexyl urea was
filtered off and the filtrate evaporated in vacuo. The residue was
dissolved in ethylacetate and subsequently washed with water,
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Fig. 1. Synthesis of naproxen-lysozyme conjugate (A). Addition of naproxen-N-hydroxysuccinimide to lysozyme results in a naproxen-lysozyme
conjugate with a peptide linkage between the free carboxylic group of naproxen and one of the free amino-groups of lysozyme. (B) Qualitative
distribution of naproxen molecules covalently coupled to lysozyme molecules in the conjugate. A qualitative measurement by ion spray mass-
spectrometry. (C) Effect of naproxen conjugation on the net charge of lysozyme. Separation of native lysozyme and conjugate was performed on a cation
exchange column. The lower solid line represents conjugated naproxen measured by fluorescence detection. The upper line represents conjugated
lysozyme (left) and native lysozyme (right), both measured by ultraviolet detection.
saturated NaHCO3, water and saturated NaCl solution. After
drying on Na2SO4, the solvent was evaporated. The material was
purified by crystallization overnight at 4°C with EtAc/petroleum
ether 40/60 twice. The overall yield was 2.45 g Nap-NHS (87%),
and the molecular weight of the product was verified with mass
spectrometry. The melting point was 116°C.
Synthesis and characterization of the naproxen-lysozyme
conjugate
Conjugation between naproxen was based on a peptide-binding
between the carboxylic group of naproxen and available free
amino-groups of lysozyme. Synthesis and characterization of the
naproxen-lysozyme conjugate was basically performed as de-
scribed by Franssen at al [8]. Briefly, 10.5 mg (30 rmo1) naproxen-
NHS in 6 ml dioxane was added in a drop-wise fashion to 140 mg
(10 jsmol) lysozyme in 24 ml (50 mM) Na2HPO4. Subsequently,
the solution was stirred for two hours. After centrifugation (2000
r.p.m, 10 mm) to remove insoluble products, uncoupled naproxen
and other small remaining products were removed by separation
on the basis of molecular weight differences using a Sephadex
G-25 column (Pharmacia, Woerden, The Netherlands) with diox-
ane/water 80/20 vol/vol eluens. The protein fraction of the column
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was washed with water and concentrated in an Amicon stirred cell
concentrator using an YM3 membrane (Amicon, Beverly, MA,
USA). After lyophilization, the conjugate was stored at —20°C.
Three methods were used to characterize the conjugate. (1)
The average coupling degree of naproxeri to lysozyme was deter-
mined by measuring the protein concentration [9] in combination
with either a direct fluorescence detection of the conjugated
naproxen (Spectrofluorometer, model SPF-500 C ; SLM &
Aminco) or naproxen analysis after hydrolysis of the conjugate as
described in the HPLC section. (2) Ion spray mass-spectrometry
was employed to qualify the variation in amount of naproxen per
mole of lysozyme [10]. (3) The charge of the conjugate was
compared with that of lysozyme by cation exchange chromatog-
raphy. Briefly, conjugate or lysozyme was separated on the cation
exchange column Mono-S (Pharmacia) using a mobile phase of
NaC1 (0.2 M) and Tris (10 mM)/HC1 (pH 7.2) 0.5 mi/mm. This
method was also used for purification of the conjugate and
characterization of the iodinated products.
Radiolabeling
For body distribution studies by external counting, 123iodine
was introduced in lysozyme with a supposed incorporation in the
tyrosine residue of the protein molecule. To ensure radiolabeling
of only the naproxen conjugated lysozyme, possible contaminating
native lysozyme molecules were removed by separation on a
cation exchange column beforehand. The conjugate fraction was
dialyzed against water with a Spectra/Por membrane with a 3,500
molecular weight cut off (Spectrum Medical Industries, Houston,
TX, USA) and lyophilized before radiolabeling. Conjugate and
native lysozyme were iodinated using the chloramine-T method as
described previously [11]. '23lodine was chosen as radiolabel to
allow in vivo imaging by external counting. The efficiency of iodine
labeling was high for both compounds: 90% (conjugate) and 99%
(lysozyme) iodine incorporation. Cation exchange showed no
detectable amounts of radiolabeled native lysozyme molecules in
the batch of '231-conjugate.
Protocol for the in vivo study focusing on the lysozyme moiety
To study the influence of naproxen conjugation on the body
distribution of lysozyme, the lysozyme moiety of the conjugate was
radiolabeled and followed in vivo by external y-radiation scan-
ning. Male Wistar rats (250 g) were anesthetized with pentobar-
bital intraperitonally (60 mg/kg) and placed on a low-energy
collimator of a gamma camera. The rats received either 1 MBq of
1231-conjugate mixed with 2 mg of unlabeled conjugate in 0.5 ml of
5% glucose (N = 12) or, as a comparison, equimolar amounts of
the free components of the conjugate, that is, native 231-ly-
sozyme, lysozyme and naproxcn in 0.5 ml 5% glucose (N = 12).
The solutions were administered intravenously as a bolus via the
dorsal penal vein. The radioactivity was recorded for 120 minutes
with a one minute resolution.
The radioactivity time course of the right kidney was plotted
after analysis of the respective "regions of interest" from the
image of the rat on the screen of the gamma-camera (Fig. 2A) as
previously described [11].
Protocol for the in vivo study focusing on the naproxen moiety
In a separate group of rats, the influence of lysozyme-conjuga-
tion on the renal disposition of naproxen was studied. The amount
of naproxen in plasma and kidney was determined at different
time intervals after intravenous injection of conjugate or unbound
naproxen. Under a light anesthesia of Forene/02, male Wistar
rats (250 g) received either 2mg of conjugate in 0.5 ml 5% glucose
or equimolar amounts of lysozyme and naproxen (47 1ag) via the
dorsal penal vein. At 5, 10, 30, 120 or 240 minutes after injection,
rats (N = 3) were anesthetized (Forene/02), blood was collected
and the kidneys exturbated after being flushed with water. The
kidneys were lyophilized and stored together with the plasma at
—20°C until analysis.
Protocol for the pilot study of in viva effects
A female Wistar rat (230 g) was kept on a low-salt diet (0.05%
NaCI/20% protein; Hope Farm Inc. Woerden, The Netherlands).
One week before the experiment, the jugular vein was cannulated
to allow a chronic drug administration intravenously. Throughout
the experiment, the rat was housed in a metabolic cage and was
given food and tap water ad libitum. The first three days of the
experiment, the rat was injected with vehicle (5% glucose, 1 mi/kg
rat) twice a day (at 8:30 a.m and 4:30 p.m). Thereafter, the rat was
treated for three days with 8.5 mg/kg conjugate (0.25 mg/kg
conjugated naproxen) twice a day. Then the dose of conjugate was
raised to 85 mg/kg conjugate two times a day. Urine was collected
for 24 hours at 4°C and stored at —20°C until analysis. Prosta-
glandin E2 concentration in the urine was measured by enzyme
immunoassay.
HPLC analysis of naproxen
The average amount of naproxen in the conjugate and the
plasma and renal concentrations of naproxen were measured by
HPLC, with minor modifications as described by Franssen et al
[6]. The HPLC determination of naproxen was performed using a
Jasco pump (model 880 PU, Tokyo, Japan) and a Jasco autosam-
pier (model 851-AS). The separation column was a jLBondapak
C18 (30 cm X 3.9 mm I.D.; Millipore Waters, Milford, MA, USA)
guarded with a jiBondapak C18 Guard-pak precolumn (Millipore
Waters). The HPLC peak integration was performed using the
integration software JCL6000 (Jones Chromatography, Littleton,
CO, USA). The mobile-phase consisted of water/acetonitrile 1/1
and 1% of acetic acid. The flow rate was 1 mi/mm. Naproxen was
detected with a fluorescence detector (Jasco model 820 EP),
operating at excitation wavelength of 330 nm and emission
wavelength of 360 nm. Ketoprofen was used as internal standard
and recorded simultaneously at 254 nm (Jasco model 875-UV).
The retention time of naproxen and ketoprofen was about 12 and
20 minutes, respectively.
After lyophilization, the soft renal tissue was weighed and
pulverized to a homogenous powder. The large renal arteries and
veins remained, though, which allowed an easy removal of these
contaminating parts. Dried renal tissue (20 mg) was added to
water (1 ml) and extensively disrupted and homogenized by
ultrasonic sound using a Vibra cell (Sonics and Materials, Dan-
bury, CT, USA).
Naproxen was determined after an extraction procedure.
Plasma (10 l diluted with water to 100 jtl) or 100 jd kidney
homogenate was added to 100 j.d NaOH 6 N. The extraction was
performed after hydrolysis for 48 hours at 80°C to release
naproxen from the conjugate. The samples were subsequently
acidified with 150 jil of HCI 6 N. After this, I ml of dichlorometh-
ane and 0.4 jg ketoprofen (100 d 4 g/ml) was added and mixed
for one minute. Of the organic layer, 400 pA was transferred to an
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Fig. 2. Body distribution of naproxen-'231-lysozyme conjugate and native
'231-lysozyme (A). Representative images, with a one minute resolution,
about 20 minutes after an intravenous injection of naproxen-'231-lysozyme
conjugate (left) and native '231-lysozyme (right) in the rat. (B) Renal
time-course of naproxen-'231-lysozyme conjugate and native 1231-lysozyme
after an intravenous injection in 12 rats. Values are given as mean + SCM
for conjugate and mean — SEM for native lysozyme.
autosampler vial and evaporated. The residue was dissolved in 400
l eluents to make it suitable for HPLC analysis. The fraction of
unbound naproxen present in the conjugate and unbound
naproxen and naproxen-lysine in plasma was determined by the
same procedure without hydrolysis for 48 hours, 80°C.
Kinetic and statistical analyses
The renal half life and total amount of the naproxen-lysozyme
conjugate that was finally taken up in the kidney was calculated
from the time-course of radioactivity (protein moiety) or
naproxen (drug moiety) in the kidney using a computer program
for non-linear curve-fitting, MultiFit (Department of Pharmaco-
kinetics and Drug Delivery, University Center of Pharmacy,
Groningen, The Netherlands), using the simplex algorithm [121.
All data are expressed as mean SEM, except for the half life of
conjugate obtained from the renal tissue concentration time curve
of naproxen, for which the standard error is given.
RESULTS
Synthesis and characterization
The reaction of 3 mol of preactivated naproxen with 1 mol
lysozyme (Fig. 1A) resulted in a conjugate with an average
coupling degree of 2.0 mol naproxen to 1 mol of lysozyme. The
amount of uncoupled naproxen was less than 0.1%. Qualitative
mass analysis showed conjugates with different degrees of cou-
pling: 0, 1, 2, 3 and 4 mol of naproxen to 1 mol of lysozyme (Fig.
1B). Since coupling of the naproxen molecules masks the posi-
tively-charged amino groups of lysozyme, a reduced retention of
lysozyme on a cation exchange column was anticipated. Indeed, a
retention of 10 minutes was found for the conjugate as compared
to 20 minutes for lysozyme (Fig. 1C). The 2 to 1 mol conjugate
used in the present study had a limited solubility in saline but
could be dissolved readily in 5% glucose up to 25 mg/mI. A
naproxen load of more than the 2 to 1 mol lysozyme seriously
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Fig. 3. Plasma naproxen as a function of time after an intravenous
injection of parent naproxen and conjugated naproxen in three rats at
each indicated time point. Plasma disappearance of naproxen after
injection of parent naproxen (dotted line, closed circles) and plasma
disappearance of conjugated naproxen after injection of conjugate (solid
line, closed circle). Plasma concentration of parent naproxen after injec-
tion of naproxen-lysozyme conjugate (open circles). Values are given as
mean + SCM.
reduced the solubility of the conjugate in water as well as in 5%
glucose and was disregarded for the present study.
Lysozyme kinetics
The effect of naproxen conjugation on the renal uptake and
degradation of lysozyme was studied in the rat by external
y-radiation counting. Qualitative analysis showed a striking simi-
larity in the body distribution of native lysozyme and conjugate
(Fig. 2A). Comparison of the concentration time-course of con-
jugate and native lysozyme in the kidney (Fig. 2B) revealed that
conjugation did not affect the renal handling of lysozyme. Both
proteins were rapidly taken up by the kidneys, with a maximum
content of 1360 140 counts per minutes (conjugate) and 1240
100 counts per minutes of radioactivity (lysozyme) at 18 minutes
after injection. Quantification with a kinetic analysis of the
radioactivity in the kidneys, as described previously [11], revealed
that 68 4% (conjugate) and 67 3% (lysozyme) of the injected
dose was finally taken up by the kidneys. Eighteen minutes after
injection, the apparent intrarenal rate of degradation of both
proteins exceeded the rate of uptake, as indicated by the subse-
quent gradual decrease in renal radioactivity. The disappearance
of the tissue radioactivity half-life appeared to be in the same
order for conjugate (283 40 mm) and native lysozyme (228 26
mm; P < 0.05).
Naproxen kinetics
Conjugation of naproxen and lysozyme resulted in an increased
plasma clearance of naproxen compared to unbound naproxen
(Fig. 3). Since a reduction in extrarenal side effects is one
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Fig. 4. RenaJ time course of naproxen after an intravenous injection of
parent naproxen or conjugate in three rats at each indicated time point.
The line with open circles represent the parent naproxen after injection of
parent naproxen. The line with closed circles represent conjugated
naproxen after injection of conjugate. Values are given as mean + SCM.
objective of drug targeting, it was encouraging to establish that no
detectable amount of free naproxen was present in the plasma
after administration of conjugate.
As shown in Figure 4, conjugation to lysozyme resulted in a
pronounced increase of naproxen accumulation in the kidney
(6.19 0.5 and 0.09 0.03 jrg/kidney at 30 mm after injection for
conjugated and unbound naproxen, respectively). In agreement
with the gamma camera studies, the naproxen-conjugate was
rapidly taken up by the kidneys and subsequently degraded, as
indicated by the gradual lowering of the total naproxen tissue
content with time. The rate at which naproxen and potential
metabolites left the kidney was significantly faster (t½ = 156 28
mm) than that of the radiolabeled breakdown products derived
from the lysozyme-moiety of the conjugate (t½ = 283 40 mm)
(P < 0.05).
Urinary excretion of prostaglandin E2
This preliminary study shows that a daily treatment of 0.5 mg/kg
conjugated naproxen did not reduce urinary excretion of prosta-
glandin E2 (POE2). However, during an intravenous treatment of
5 mg/kg/day conjugated naproxen, PGE2 excretion was reduced by
50% (Fig. 5).
DISCUSSION
in the present study, a well defined naproxen-lysozyme conju-
gate with an average coupling degree of 2 mol of naproxen to 1
mol of lysozyme was studied in vivo with emphasis on the renal
kinetics of both the lysozyme and naproxen-moiety of the conju-
gate. The data show that renal specific targeting of naproxen is
indeed obtained by conjugation of the drug to lysozyme.
In agreement with previous studies [11, 13], a significant
amount of intravenously injected native lysozyme rapidly accumu-
lated in the kidneys with a subsequent slowing of intrarenal
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Fig. 5. Urinary excretion of prostaglandin E2 after daily intravenous
injection of vehicle, low dose conjugate and high dose of conjugate,
respectively. A typical example of a rat treated with vehicle (days ito 3),
with 0.5 mg/kg/day conjugated naproxen (days 4 to 6) and with 5
mg/kg/day conjugated naproxen (days 7 to 9).
degradation. Conjugation of lysozyme with the drug naproxen did
not affect these characteristics of renal delivery and breakdown of
the LMWP. Thus, in spite of the conjugation, lysozyme remains
renal specific and accessible to renal degradation and is therefore
suitable to serve as a renal specific carrier of naproxen. In
contrast, focusing on the drug moiety of the conjugate, conjuga-
tion of naproxen using lysozyme distinctly altered the kinetics of
the drug. The plasma disappearance of intravenously injected
conjugated and unbound naproxen were largely different, with a
more rapid disappearance of conjugated naproxen from the
circulation. In the kidney, naproxen accumulated about 70 times
more if the drug was administered in the conjugated form. Until
now, no other renal targeting strategy has shown such a high
relative enrichment of a drug in the kidney [14].
The apparent renal accumulation of conjugated naproxen,
measured directly by analyzing the dissected kidney, was about
two times lower than that found in the gamma-radiation lysozyme
experiment. Extrapolation of the renal tissue concentration time
curve to time of injection revealed that about 30% of conjugated
naproxen was taken up by the kidneys, while the lysozyme
gamma-imaging study indicated that 70% of the injected dose
entered the renal compartment. One possible explanation for this
discrepancy may be that iodine and naproxcn were not equally
distributed over the conjugate molecules. As a result, the iodine
kinetics we presented may not fully represent the kinetics of all
conjugate molecules, but may reflect only part of conjugate with a
certain load of naproxen. Second, the calibration procedure of the
gamma-camera may be partly incorrect. Lastly, we may underes-
timate the renal concentration of total naproxen, for example, due
to an incomplete extraction of naproxen from the tissue. In spite
of this as yet unresolved discrepancy, the 70 times difference in
renal accumulation of naproxcn after injection of free and conju-
gated naproxen clearly indicates a successful renal selective
targeting of the drug.
The rate of degradation of the naproxen-lysozyme conjugate in
the kidney as calculated on the basis of the time-course of renal
'23iodine activity was lower than that of the time-course of
naproxen content in the kidney. This difference may be explained
by an unequal accessibility of the protein backbone contacting the
two labels by the proteolytic enzymes in the lysosomes of the
proximal tubular cell, or by a change in affinity for particular
degradation enzymes as the consequence of iodine or naproxcn
labeling. Alternatively, the difference may be explained by an
unequal rate of renal release of the two breakdown products.
In an earlier study [6], it was suggested that a part of naproxen-
lysozyme conjugate is liberated in the kidney as naproxen-lysine
and that this active metabolite is at least partly excreted to the
blood, finally to be excreted in the gut. However, in that particular
study, taking into account that the naproxen content in the kidney
was not measured, the plasma levels of naproxen-lysine were
undetectable and the solubility of the conjugate was rather poor,
it cannot be excluded that the naproxen-lysine in the gut originat-
ing from conjugate was extracted by the liver. In contrast, in the
present study, a renal selective uptake of conjugated naproxen was
proven by the detection of naproxen in the kidney.
The present study is the first preliminary report of a renal effect
of naproxen-lysozyme conjugate. Treatment with the conjugate
resulted in a reduced urinary excretion of prostaglandin E.
Together with the fact that no detectable amounts of free
naproxen or active metabolite were found in the circulation, it
seems reasonable to conclude that a renal specific effect of
naproxen was obtained successfully by coupling the drug to
lysozyme. Since the ultimate goal of renal targeting of naproxen is
the treatment of proteinuria, the question may arise as to whether
the proximal tubular cell is an appropriate site of naproxen
release, and whether a reduced PGE2 excretion is an indication
that the conjugate will be effective in reducing proteinuria. In
patients with the nephrotic syndrome, the degree of reduction of
proteinuria by NSAID treatment correlates with the degree of
reduction of urine prostaglandin E2 excretion [15]. However, little
is known about the mechanism by which NSAIDs reduce protein-
uria. Glomerular and vascular prostaglandins are directly involved
in the hemodynamic regulation while the tubular and interstitial
prostaglandins indirectly regulate the hemodynamics by control of
homeostasis and hormonal stimulation [161. Since naproxen re-
leased from the proximal tubular cell may only reach its cyclo-
oxygenase targets downstream and not those of the glomerulus,
the use of the naproxen-lysozyme conjugate may provide an
opportunity to study the direct and indirect involvement of
prostaglandins in the regulation of hemodynamics and protein-
uria.
In summary, renal specific targeting of the NSAID naproxen
can be obtained by conjugation with the LMWP lysozyme. This
conjugate is renal selective and biodegradable, while after renal
uptake and degradation of the conjugate free naproxen is not
detected in the systemic circulation. This renal targeting concept
may provide the opportunity to improve the therapy of kidney
diseases and to increase the knowledge of renal pharmacology.
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The concept may be further elaborated by the use of other types
of renal-specific drug carriers such as tailor-made synthetic poly-
mers, or by the coupling of other kind of drugs such as angiotensin
converting enzyme (ACE)-inhibitors and anti-inflammatory ste-
roids. Also, selective targeting to other renal compartments such
as glomerular endothelial and mesangial cells are attractive
options for further study.
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